It can thus be foreseen that using agents that restore p53 function (such as the MDM2 inhibitors) or immunological agents like Rituximab in pairing with agonistic TRAIL antibody could enhance responses to standard chemotherapy agents by overcoming tumor cell resistance. This evidence concerns the gene TP53 and neoplasm.